| abstract |
REFERS TO UREAS 1- (N-ARILS SUBSTITUTED) -1-N- (2-PYRIMIDIN-4-IL SUBSTITUTED) -3-N- (ALKYL ALKYL SUBSTITUTED, OF FORMULA (I), WHERE R IS RENTED (C1- C10) LINEAR OR BRANCHED, OPTIONALLY SUBSTITUTED; R1 IS - (L) x-R3, WHERE x IS 0 OR 1, R3 IS 4-METOXYPHENYL, 4-ETHOXYPHENYL, 4-FLUOROPHENYL, AMONG OTHERS; R2 IS - (L1) y-R4, SUCH AS (R) O (S) -2-HYDROXY-1,2-DIMETHYLPROPYLAMINE, (R) O (S) 2-METHOXY-1-METHYLETHYLAMINE, AMONG OTHERS. PREFERRED COMPOUNDS: 1- (4 -METOXY-PHENYL) -1- {2 - [(1S) -2-METHOXY-1-METHYLAMINE] -PYRIMIDIN-4-IL} -3-METHYLUREA, 1- (FLUORO-PHENYL) -1- {2- [ (1S) -2-METOXY-I-1-METHYLAMINE] -PYRIMIDIN-4-IL} -3-METHYLUREA, AMONG OTHERS. ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. THESE COMPOUNDS INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES SUCH AS INTERLEUKIN-1 (IL-1) AND THE TUMOR NECROSIS FACTOR (TNF) FOR WHICH THEY ARE USEFUL IN THE TREATMENT OF INFLAMMATORY DISEASES, RHEUMATOID ARTHRITIS OR OSTEARTHRITIS, INFLAMMATORY INTESTINAL DISEASE, SEPTIC SHOCK, CARDIOPULMONARY DYSFUNCTION, AND RESPIRATORY DISEASE OR CAQUEXIA |